







III SESSIONE:

Trattamento neoadiuvante del carcinoma mammario HER2-positivo/recettori ormonali positivi

ormonali positivi

Lo studio TBCRC-023: Commento sulla metodologia



Emilio Bria

emilio.bria@univr.it

Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona



Pescantina (VR), 10 Aprile 2015

Disclosures

- Advisory Boards/Honoraria/Consultant for:
 - Celgene
 - Astra-Zeneca
 - Helsinn
 - Eli-Lilly
 - BMS
- Research Support / Grants from:
 - A.I.R.C. (Associazione Italiana Ricerca sul Cancro)
 - I.A.S.L.C. (International Association for the Study of Lung Cancer)




'Comments' upon Methodology

- Protocol Analysis
 - Presentation from SABCS 2014
- Supporting background & Rationale
 - Preclinical evidences
 - Single arm Phase II [TBCRC06]
 - Was the benchmarking appropriate?
- Demographics
 - Do patients characteristics overlap TBCRC06?
- Choice of end-point
 - pCR
 - Achieved or not?
 - What's now on?
 - Data Attrition
 - Safety, Biopsy rate



Supporting Background & Rationale




Arpino, JNCI 2007

Dave, JCO 2011

Rimawi, CCR 2011

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Single-Arm Phase II



Rimawi, JCO 2013

Hypothesis

 We hypothesized that in HER2+ breast cancer, longer treatment with anti-HER2 therapy and endocrine therapy, if tumors are also ER+, will result in higher pCR rate.

Study Design

- Randomized Unblinded Phase II
 - **No-Profit Fashion**











Single Arm Phase II Trial




Courtesy of Billingham C, 2008

Types of phase II studies



Seymour L, CCR 2010

TBCRC023 Schema




Study Timeline • Nov. 2011-Nov. 2013: Accrual to main study • April 2013: Addition of expansion cohort (to cohort.

'Benchmarking' the Activity: [HER2+]–Dual Blockade

Heavily Metastatic

LABC/IBC/Operable



Gianni, Lancet Oncol 2011

Blackwell, JCO 2010


'Benchmarking' the Activity: [HER2+] - ER-Positive


Metastatic Disease - Letrozole

Letrozole 2.5 mg + placebo

LAP-Trast

Letrozole 2.5 mg + lapatinib 1,500 mg





ELECTRA

Huober, The Breast 2012

'Benchmarking' the Activity: [HER2+] - ER-Positive

Metastatic Disease [Other Hormonal]

40 38 Trastuzumab + 35 Anastrozole (n = 74) 30 No. of Patients % Response 25 20 17 0 Complete response* 0 15 20.3† Partial response 15 Stable disease 37.8 10 28 Progressive disease 30 40.5 5 Not evaluable 1.4 0 FUL FUL + LAP

Kaufman, JCO 2009

TANDEM

Burnstein, JCO 2014

CALGB 40302

Study Design

- Primary endpoint is pathologic complete response (pCR) in the breast (ypT_{0-is} ypN_x).
- Secondary endpoints included: safety and tolerability, time to first recurrence, and overall survival.
 - 88-96 patients were needed to detect an increase in pCR from 27% reported in TBCRC006 to 45%, with a power of 85% and type I error of 10%.
 - Study arms were not powered to be directly comparable.

False Positive Rates of Randomized Phase II Designs

- Purpose of Randomized Phase II:
 - Selecting a treatment for eventual Phase III
 - 'Pilots' to Phase III evaluations.
 - One should not regard them as conclusive.
 - Control arms may yield erroneous inferences.


Frequent <u>misapplications</u>:

 In presence of 'impressive' difference in binary outcomes, the 'false-positive' rates range from 20% to over 40%.



Liu PY, Control Clin Trials 1999

Study Flow Diagram




Lo studio TBCRC023: Demographics: 06 vs. 023

TBCRC06				TBCRC023		
Age, years			Age	≤50	39	41%
≤ 50	34	52		>50	55	59%
> 50	31	48		Median (range)	51	(23-80)
Median	49				,	
Range	31-74		Pasa	White	73	78%
Race			Race			
White	48	74		Black	16	17%
Black	14	21.5		Others/Unkown	5	5%
Asian	1	1.5				
American Indian	1	1.5				
Unknown	1	1.5				
Ethnicity			Ethnicity	Hispania	19	20%
Hispanic	21	32	Ethnicity	Hispanic		
Non-Hispanic	43	66		Not Hispanic	74	79%
Unknown	1	1.5		Unknown	1	1%
Menstrual status			Menstrual Status	Premenopausal	42	45%
Premenopausal	35	54		Postmenopausal	52	55%
Postmenopausal	30	46		. comenopaasa		

Rimawi, JCO 2013

Lo studio TBCRC023: Demographics: 06 vs. 023



Rimawi, JCO 2013

Safety: 06 vs. 023

TBCRC06					
		Grades	Grades 3 and 4		
	Adverse Event	No.	%		
GI					
Di	arrhea	2	3		
Na	ausea	0	0		
He	eartburn/dyspepsia	0	0		
M	ucositis/stomatitis	0	0		
Hep	atic				
Al	T	3	5		
AS	ST	4	6		
AI	kaline phosphatase	0	0		
El	evated bilirubin	1	2		
Skin					
Ra	ash	1	2		
Dr	y skin/other	0	0		
Con	stitutional				
Fa	tigue	0	0		
Ho	ot flashes	0	0		
Ar	norexia	0	0		
Labo	oratory				
Ar	nemia	0	0		
Hy	/pokalemia	0	0		
Hy	/perglycemia	1	1.5		
Hy	/pocalcemia	0	0		
Hy	/ponatremia	0	0		


TBCRC023

Grade 3 Toxicity	12 Week N (%)	24 Week N (%)
Elevated LFT	-	5 (9%)
Diarrhea	-	1 (2%)
Mucositis	-	1 (2%)
Anemia	1 (3%)	
Renal calculi (SAE)	1 (3%)	

No grade 4 toxicity


Rimawi, JCO 2013

Lo studio TBCRC023: pCR according to ER: 06 vs. 023




Rimawi, JCO 2013; Rimawi, SABCS 2014


Lo studio TBCRC023: TARGET pCR: 06 vs. 023




Lo studio TBCRC023: pCR [ER-Negative]: 06 vs. 023



Lo studio TBCRC023: pCR [ER-Positive]: 06 vs. 023



(Endocrine) Neoadjuvant Treatment Duration



Llombart-Cussac CTO 2012

Ellis JCO 2011

Fontein EJC 2014

(Endocrine) Neoadjuvant Treatment Duration


Neoadjuvant endocrine trials.

Author or trial name	Number of patients	Design	Duration (month)	Clinical ORR ^e
IMPACT ²	330	ANA ^a vs TAM ^b vs ANA + TAM	3	37%, 36%, 39%
PROACT ³	451	ANA vs TAM	3	49.7%, 39.7%
PO24 Trial ⁴	337	LET ^c vs TAM	4	55%, 36%
GENARI Trial ⁵	29	EXE ^d	4	37.0%
French study ⁶	45	EXE	14–27	70.6%
			weeks	
Gil Gil (Spain) ⁷	55	EXE	6	50%
Mustacchi ⁸	44	EXE	6	66%

• Data almost exclusively gathered from trials with Als in HER2 negative disease!


Hojo, The Breast 2013

Lo studio TBCRC023: Small residual [≤1 cm] according to ER



Rimawi, SABCS 2014


Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies



Conclusion

This meta-regression analysis of 29 heterogeneous neoadjuvant trials does not support the use of pCR as a surrogate end point for DFS and OS in patients with breast cancer. However, pCR may potentially meet the criteria of surrogacy with specific systemic therapies.

- Endocrine therapy-based trials were excluded because pCR is uncommon after short-term preoperative endocrine therapy
 - Burzykowski T, et al. The Evaluation of Surrogate Endpoints. New York, NY, Springer, 2005



Berruti A, JCO 2014

Conclusions

- TBCRC023 did not meet its primary endpoint of increasing pCR to 45%. This was mainly due to lower than expected pCR in both arms.
- However, our study demonstrated a twofold numeric increase in pCR in the 24 weeks arm over the 12 week arm. That increase was more than threefold in the ER+ subgroup.
- This is the first trial to show that longer treatment with dual anti-HER2 therapy in combination with endocrine therapy, and without chemotherapy, *leads to a meaningful increase in pCR rate in ER+/HER2+ breast cancer*.

Lo studio TBCRC023: Commento sulla metodologia

Conclusions

- First: let's wait for the final paper....
 - Additional data missing, safety (crucial anyway for phase II), biopsy rate, etc.
- Primary end-point not met!
 - Less than what expected in the control arm
 - Patients' selection bias?
 - Overall smaller difference than expected between 12 and 24 wks
 - ER-Negative did benefit more from dual HER2 blockade
 - Similar data from Trial 06 and Trial 023.....and consistent with NeoSphere
 - ER-Positive did benefit more from longer treatment
 - Hormonal therapy: the longer, the better!
 - Treatment duration for triple-positive disease still unclear
- Is pCR really useful as a 'pre-requisite' (not a surrogate) for overall outcome in the context of hormonal therapy, as well as for chemotherapy?

